Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Oral administration of Lactiplantibacillus plantarum GKK1 ameliorates atopic dermatitis in a mouse model.

Study Design

Population
Five-week-old BALB/c mice
Methods
mice were divided into four groups (n = 8): control, AD, low-dose GKK1 (10^7 CFU/day), and high-dose GKK1 (10^9 CFU/day). GKK1 was intragastrically administered daily for 42 days. AD symptoms, skin histology, serum antibodies, inflammatory cytokine levels, gut microbiota composition, and short-chain fatty acids (SCFAs) in the intestines were assessed.

Background/objectives

Atopic dermatitis (AD) is a prevalent chronic skin condition, especially in young children, with rising incidence in developed countries. AD causes repeated scratching, and thus affecting quality of life. This study evaluated the effects and mechanisms of the probiotic Lactiplantibacillus plantarum GKK1 on AD symptoms in mice.

Methods

Five-week-old BALB/c mice were divided into four groups (n = 8): control, AD, low-dose GKK1 (107 CFU/day), and high-dose GKK1 (109 CFU/day). GKK1 was intragastrically administered daily for 42 days. AD symptoms, skin histology, serum antibodies, inflammatory cytokine levels, gut microbiota composition, and short-chain fatty acids (SCFAs) in the intestines were assessed.

Results

GKK1 showed improved skin appearance and reduced inflammation in AD mice, with high-dose GKK1 significantly reducing histological inflammation. The GKK1 treatment upregulated splenic interleukin (IL)-2, suppressed IL-4, IL-5 and IL-17 levels and increased intestinal Lactobacillus and Bifidobacterium spp., contributing to higher SCFAs production in intestine.

Conclusion

Oral L. plantarum GKK1 effectively ameliorated AD symptoms and reduced inflammation in mice. Therefore, L. plantarum GKK1 may serve as a potential treatment for AD.

Research Insights

Back to top